Hepatitis Monthly

Published by: Kowsar

PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings

James S Leathers 1 , * , Domingo Balderramo 2 , Jhon Prieto 3 , Fernando Diehl 2 , Esteban Gonzalez-Ballerga 4 , Melina R Ferreiro 4 , Enrique Carrera 5 , Fernando Barreyro 6 , Javier Diaz-Ferrer 7 , Dupinder Singh 8 , Angelo Z. Mattos 9 , Flair Carrilho 10 and Jose D. Debes 8 , **
Authors Information
1 School of Medicine, Vanderbilt University, Nashville, USA
2 Department of Gastroenterology, Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina
3 Centro de Enfermedades Hepaticas y Digestivas (CEHYD), Bogota, Colombia
4 Department of Gastroenterology, Hospital Clinicas, Buenos Aires, Argentina
5 Departament of Gastroenterology and Hepatology, Hospital Eugenio Espejo, Quito, Ecuador
6 Consejo Nacional de Investigaciones Científicas y Técnicas, Posadas, Argentina
7 Department of Gastroenterology, Hospital Nacional Edgardo Rebagliati Martins (HNERM), Lima, Peru
8 Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
9 Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil
10 Department of Gastroenterology, School of Medicine, University of São Paulo, São Paulo, Brazil
Corresponding Authors:
Article information
  • Hepatitis Monthly: October 2018, 18 (10); e82345
  • Published Online: October 21, 2018
  • Article Type: Brief Report
  • Received: July 18, 2018
  • Revised: September 18, 2018
  • Accepted: October 9, 2018
  • DOI: 10.5812/hepatmon.82345

To Cite: Leathers J S, Balderramo D, Prieto J, Diehl F, Gonzalez-Ballerga E, et al. PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings, Hepat Mon. 2018 ; 18(10):e82345. doi: 10.5812/hepatmon.82345.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. [PubMed: 25220842].
  • 2. Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, et al. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver Int. 2018;38(1):136-43. doi: 10.1111/liv.13502. [PubMed: 28640517].
  • 3. Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, et al. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Target Oncol. 2017;12(6):795-803. doi: 10.1007/s11523-017-0522-5. [PubMed: 28770532].
  • 4. Leathers SJ, Balderramo D, Prieto J, Diehl F, Gonzalez-Ballerga E, Ferreiro MR, et al. Sorafenib for treatment of hepatocellular carcinoma: A survival analysis from the South American liver research network. J Clin Gastroenterol. 2018. doi: 10.1097/MCG.0000000000001085. [PubMed: 29952857].
  • 5. Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, et al. Novel pretreatment scoring incorporating c-reactive protein to predict overall survival in advanced hepatocellular carcinoma with sorafenib treatment. Liver Cancer. 2016;5(4):257-68. doi: 10.1159/000449337. [PubMed: 27781198]. [PubMed Central: PMC5075810].
  • 6. Edeline J, Blanc JF, Campillo-Gimenez B, Ma YT, King J, Faluyi O, et al. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer. 2017;86:135-42. doi: 10.1016/j.ejca.2017.08.036. [PubMed: 28987770].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments